Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
NiKang Therapeutics, Inc.
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
Eli Lilly and Company
BeOne Medicines
Eli Lilly and Company
Seagen Inc.
Myeloid Therapeutics
Tizona Therapeutics, Inc
Normunity AccelCo, Inc.
NiKang Therapeutics, Inc.
IDEAYA Biosciences
MacroGenics
Cogent Biosciences, Inc.
SystImmune Inc.
M.D. Anderson Cancer Center
Eli Lilly and Company
Shanghai Best-Link Bioscience, LLC
Seagen Inc.
Fusion Pharmaceuticals Inc.
National Institutes of Health Clinical Center (CC)
Risen (Suzhou) Pharma Tech Co., Ltd.
GlaxoSmithKline
Fate Therapeutics
NextCure, Inc.
NeoTX Therapeutics Ltd.
SystImmune Inc.
Mersana Therapeutics
NiKang Therapeutics, Inc.
EtiraRx Australia Pty Ltd
Exelixis
Numab Therapeutics AG
Lyell Immunopharma, Inc.
AstraZeneca
NextPoint Therapeutics, Inc.
Eli Lilly and Company
Pfizer
Theratechnologies
Exelixis
Compugen Ltd
Carisma Therapeutics Inc
Acepodia Biotech, Inc.
Vincerx Pharma, Inc.
Danatlas Pharmaceuticals Co., Ltd
Xencor, Inc.
Prelude Therapeutics
Pliant Therapeutics, Inc.
Haihe Biopharma Co., Ltd.